Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc (ACXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,056
  • Shares Outstanding, K 16,893
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,580 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta -1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.79

Options Overview Details

View History
  • Implied Volatility 410.12% ( +74.51%)
  • Historical Volatility 21.48%
  • IV Percentile 96%
  • IV Rank 74.07%
  • IV High 551.41% on 10/30/24
  • IV Low 6.51% on 10/14/24
  • Put/Call Vol Ratio 0.09
  • Today's Volume 248
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 352
  • Open Int (30-Day) 356

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +52.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6300 +4.29%
on 11/15/24
2.0200 -15.84%
on 10/21/24
-0.3100 (-15.42%)
since 10/18/24
3-Month
1.6300 +4.29%
on 11/15/24
2.3900 -28.87%
on 08/22/24
-0.3100 (-15.42%)
since 08/16/24
52-Week
1.5200 +11.84%
on 04/16/24
5.2800 -67.80%
on 01/12/24
-2.0000 (-54.05%)
since 11/17/23

Most Recent Stories

More News
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week

ACXP : 1.7000 (-1.16%)
BURU : 0.4317 (+0.40%)
ZAPP : 1.7900 (-0.56%)
Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel...

ACXP : 1.7000 (-1.16%)
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 1.7000 (-1.16%)
Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as...

ACXP : 1.7000 (-1.16%)
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted...

ACXP : 1.7000 (-1.16%)
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 1.7000 (-1.16%)
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 1.7000 (-1.16%)
Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 1.7000 (-1.16%)
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 1.7000 (-1.16%)
Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET

/PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat...

ACXP : 1.7000 (-1.16%)

Business Summary

Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y.

See More

Key Turning Points

3rd Resistance Point 1.8293
2nd Resistance Point 1.7997
1st Resistance Point 1.7498
Last Price 1.7000
1st Support Level 1.6703
2nd Support Level 1.6407
3rd Support Level 1.5908

See More

52-Week High 5.2800
Fibonacci 61.8% 3.8437
Fibonacci 50% 3.4000
Fibonacci 38.2% 2.9563
Last Price 1.7000
52-Week Low 1.5200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar